Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 142

1.

Cardiovascular safety of stimulant medications for pediatric attention-deficit hyperactivity disorder.

Silva RR, Skimming JW, Muniz R.

Clin Pediatr (Phila). 2010 Sep;49(9):840-51. doi: 10.1177/0009922810368289.

PMID:
20693523
[PubMed - indexed for MEDLINE]
2.

Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.

Martinez-Raga J, Knecht C, Szerman N, Martinez MI.

CNS Drugs. 2013 Jan;27(1):15-30. doi: 10.1007/s40263-012-0019-9. Review.

PMID:
23160939
[PubMed - indexed for MEDLINE]
3.

[Cardiovascular risks and management during Attention Deficit Hyperactivity Disorder treatment with methylphenidate].

Bange F, Le Heuzey MF, Acquaviva E, Delorme R, Mouren MC.

Arch Pediatr. 2014 Jan;21(1):108-12. doi: 10.1016/j.arcped.2013.11.001. Epub 2013 Dec 3. French.

PMID:
24309201
[PubMed - indexed for MEDLINE]
4.

Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder.

Wilens TE, Hammerness PG, Biederman J, Kwon A, Spencer TJ, Clark S, Scott M, Podolski A, Ditterline JW, Morris MC, Moore H.

J Clin Psychiatry. 2005 Feb;66(2):253-9.

PMID:
15705013
[PubMed - indexed for MEDLINE]
5.

An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.

Chavez B, Sopko MA Jr, Ehret MJ, Paulino RE, Goldberg KR, Angstadt K, Bogart GT.

Ann Pharmacother. 2009 Jun;43(6):1084-95. doi: 10.1345/aph.1L523. Epub 2009 May 26. Review.

PMID:
19470858
[PubMed - indexed for MEDLINE]
6.

Stimulants and sudden death: what is a physician to do?

Wilens TE, Prince JB, Spencer TJ, Biederman J.

Pediatrics. 2006 Sep;118(3):1215-9. Review.

PMID:
16951018
[PubMed - indexed for MEDLINE]
Free Article
7.

Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.

Garnock-Jones KP, Keating GM.

Paediatr Drugs. 2009;11(3):203-26. doi: 10.2165/00148581-200911030-00005. Review.

PMID:
19445548
[PubMed - indexed for MEDLINE]
8.

Attention-deficit/hyperactivity disorder, stimulant therapy, and the patient with congenital heart disease: evidence and reason.

Batra AS, Alexander ME, Silka MJ.

Pediatr Cardiol. 2012 Mar;33(3):394-401. doi: 10.1007/s00246-012-0162-6. Review.

PMID:
22298228
[PubMed - indexed for MEDLINE]
9.

[Medication for ADHD and the risk of cardiovascular mortality].

Langendijk PN, Wilde AA.

Ned Tijdschr Geneeskd. 2006 Aug 5;150(31):1713-4. Dutch.

PMID:
16924941
[PubMed - indexed for MEDLINE]
10.

Long-term cardiovascular effects of mixed amphetamine salts extended release in adults with ADHD.

Weisler RH, Biederman J, Spencer TJ, Wilens TE.

CNS Spectr. 2005 Dec;10(12 Suppl 20):35-43.

PMID:
16344839
[PubMed - indexed for MEDLINE]
11.

An open-label study of the tolerability of mixed amphetamine salts in adults with attention-deficit/hyperactivity disorder and treated primary essential hypertension.

Wilens TE, Zusman RM, Hammerness PG, Podolski A, Whitley J, Spencer TJ, Gignac M, Biederman J.

J Clin Psychiatry. 2006 May;67(5):696-702.

PMID:
16841618
[PubMed - indexed for MEDLINE]
12.

Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.

Findling RL.

Clin Ther. 2008 May;30(5):942-57. doi: 10.1016/j.clinthera.2008.05.006. Review.

PMID:
18555941
[PubMed - indexed for MEDLINE]
13.

Do prescription stimulants increase the risk of adverse cardiovascular events?: A systematic review.

Westover AN, Halm EA.

BMC Cardiovasc Disord. 2012 Jun 9;12:41. doi: 10.1186/1471-2261-12-41. Review.

PMID:
22682429
[PubMed - indexed for MEDLINE]
Free PMC Article
14.
15.

Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.

Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.

Clin Ther. 2007 Jun;29(6):1168-77.

PMID:
17692731
[PubMed - indexed for MEDLINE]
16.

Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder.

Stiefel G, Besag FM.

Drug Saf. 2010 Oct 1;33(10):821-42. doi: 10.2165/11536380-000000000-00000. Review.

PMID:
20812768
[PubMed - indexed for MEDLINE]
17.

Comparative effects of methylphenidate and mixed salts amphetamine on height and weight in children with attention-deficit/hyperactivity disorder.

Pliszka SR, Matthews TL, Braslow KJ, Watson MA.

J Am Acad Child Adolesc Psychiatry. 2006 May;45(5):520-6.

PMID:
16670648
[PubMed - indexed for MEDLINE]
18.

Stimulants and cardiovascular events in youth with attention-deficit/hyperactivity disorder.

Olfson M, Huang C, Gerhard T, Winterstein AG, Crystal S, Allison PD, Marcus SC.

J Am Acad Child Adolesc Psychiatry. 2012 Feb;51(2):147-56. doi: 10.1016/j.jaac.2011.11.008. Epub 2011 Dec 20.

PMID:
22265361
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Cardiovascular effects of longer-term, high-dose OROS methylphenidate in adolescents with attention deficit hyperactivity disorder.

Hammerness P, Wilens T, Mick E, Spencer T, Doyle R, McCreary M, Becker J, Biederman J.

J Pediatr. 2009 Jul;155(1):84-9, 89.e1. doi: 10.1016/j.jpeds.2009.02.008. Epub 2009 Apr 25.

PMID:
19394037
[PubMed - indexed for MEDLINE]
20.

Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder.

Fallu A, Richard C, Prinzo R, Binder C.

Curr Med Res Opin. 2006 Dec;22(12):2557-66.

PMID:
17166338
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk